Trial Condition(s):

Psoriasis

BAY1003803 formulation comparison in open Psoriasis Plaque Test

Bayer Identifier:

17012

ClinicalTrials.gov Identifier:

NCT02940002

EudraCT Number:

2016-000962-47

Study Completed

Trial Purpose

To explore the efficacy and safety of four BAY1003803 formulations by means of a within subject comparison in an open Psoriasis Plaque Test

Inclusion Criteria
- Male and female (non-childbearing potential) volunteer with stable plaque-type psoriasis, but otherwise healthy
                - Age: 18-64 years
Exclusion Criteria
- Severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator 
               - Any topical antipsoriatics on plaques potentially to be treated in this trial (including corticosteroids, vitamin D analogues, immunomodulators, retinoids, dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before first treatment and/or planned during the trial, except for allowed topical treatment on the face, ears and scalp 
               - Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior and/or planned during the trial
               - Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or angiotensin-converting-enzyme inhibitors (AEC inhibitors) unless on a stable dose for 3 months before study medication initiation
             - Clinico-chemical parameters of clinically significant deviation

Trial Summary

Enrollment Goal
23
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
BAY1003803
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Hamburg, Germany, 20095

Status
Completed
 
Locations

Investigative Site

Schwerin, Germany, 19055

Status
Completed
 
Locations

Investigative Site

Bochum, Germany, 44803

Status
Completed
 

Trial Design